Oct 9 (Reuters) - Eli Lilly and Co LLY.N :
* LILLY'S INVESTIGATIONAL DUAL GIP AND GLP-1 RECEPTOR AGONIST SHOWS SIGNIFICANT REDUCTION IN HBA1C AND BODY WEIGHT IN PEOPLE WITH TYPE 2 DIABETES
* ELI LILLY AND CO - SAFETY AND EFFICACY OF LILLY'S GIP/GLP-1 RA BEING STUDIED FURTHER IN A LARGE PHASE 3 CLINICAL PROGRAM
* ELI LILLY AND CO - PHASE 3 STUDIES FOR TYPE 2 DIABETES ARE EXPECTED TO BEGIN NO LATER THAN EARLY 2019 AND COMPLETE IN LATE 2021
* ELI LILLY AND CO - EVALUATING NEXT STEPS IN STUDY OF GIP/GLP-1 RA FOR OBESITY AND OTHER CONDITIONS
* ELI LILLY AND CO - SAFETY PROFILE OF GIP/GLP-1 RA WAS SIMILAR TO GLP-1 RA CLASS